title: [In vitro antibacterial activity of a new fluoroquinolone, temafloxacin, against hospital isolates. Results of a multicenter study].
abstract: Minimal inhibitory concentrations (MICs) of temafloxacin (TMF) was determined by agar dilution for 2,510 bacterial strains isolated in 1989 in 9 university hospitals. Activity of TMF against nalidixic acid (NAL) susceptible (S) Enterobacteriaceae was close to that of other fluoroquinolones (FQ) (mode MIC: 0.06 micrograms/l); like for other FQ, this activity was reduced against NAL intermediate (mode 1) and resistant (R) (mode 4) Enterobacteriaceae. MICs of TMF against P. aeruginosa were between 0.12 and 128 (mode 0.5-1). TMF had also a good activity against NAL S A. baumannii (mode MIC: 0.06-0.12) but this activity is reduced against NAL R Acinetobacter (mode MIC: 16). TMF was highly active against Haemophilus mode MIC: less than or equal to 0.008), Gonococci (mode MIC: 0.008-0.032), Meningococci (mode MIC: 0.08) and B. catarrhalis (mode MIC: 0.016). TMF showed better activity to other fluoroquinolones against methicillin susceptible Staphylococci (mode MIC: 0.06); the resistant strains (mode MIC: 8) are usually methicillin resistant. Comparatively to the currently available FQ, TMF is so more effective against Enterococci (mode MIC: 1), Streptococci (mode MIC: 0.5-1) and Pneumococci (mode MIC: 0.5). Finally, for the anaerobic bacteria, TMF is more active against C. perfringens (mode MIC: 0.5) than against B. fragilis (mode MIC: 2).
authors.affiliation: Service de Bactériologie, CHU Herni Mondor, Creteil.
authors.forename: C J
authors.initials: CJ
authors.lastname: Soussy
authors.forename: C
authors.initials: C
authors.lastname: Morel
authors.forename: M D
authors.initials: MD
authors.lastname: Kitzis
authors.forename: M
authors.initials: M
authors.lastname: Meyran
authors.forename: Y
authors.initials: Y
authors.lastname: Brun
authors.forename: M L
authors.initials: ML
authors.lastname: Joly-Guillou
authors.forename: H
authors.initials: H
authors.lastname: Dabernat
authors.forename: M
authors.initials: M
authors.lastname: Chanal
authors.forename: A L
authors.initials: AL
authors.lastname: Courtieu
authors.forename: E
authors.initials: E
authors.lastname: Derlot
mesh_terms: D042462:4-Quinolones; D000150:Acinetobacter / Q000187:drug effects*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004755:Enterobacteriaceae / Q000187:drug effects*; D024841:Fluoroquinolones; D006190:Haemophilus / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D009343:Neisseria / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects*; D015363:Quinolones; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C054745:temafloxacin
vernacular_title: Activité antibactérienne in vitro d'une nouvelle fluoroquinolone, la témafloxacine, sur les bactéries hospitalières. Résultats d'une étude multicentrique.